Product Images Losatan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Losatan Potassium NDC 51655-258 by Northwind Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
51655-258-30 - 51655 258 30
This medication is a type of losartan and is manufactured and distributed by Alembic Pharmaceuticals in India and Northwind Pharmaceuticals in the United States. The lot number is 1705000352 and is available in a container with a child-resistant closure. The tablets contain 25mg of potassium, USP. It is recommended to store the medication at a temperature between 68-77 degrees F and to keep it out of reach of children. For more information on how to take this medication, see the prescribing information provided. A medication guide is available at the website www.fda.gov/drugs/drugsafety/ucm085729.*
30's bottle pack - losartan 25mg
Figure 1 - losartan fig1
Figure 2 - losartan fig2
The text appears to be a table or chart that compares the effectiveness of two medications (Atenolol and Losartan Potassium Tablets) in reducing the risk of fatal or non-fatal strokes in patients. It shows an adjusted risk reduction of 25% for one of the medications with a statistical significance (p-value) of 0.001. The numbers on the bottom row may correspond to the duration of the study in months.*
Figure 3 - losartan fig3
This appears to be a table of results (labeled Figure 3) divided into demographic subgroups for a study comparing the effectiveness of two hypertension medications, losartan potassium tablets and atenolol, in reducing the incidence of stroke. The primary composite endpoint was stroke (fatal or non-fatal) with event rates presented for each subgroup. The table includes subgroups for age, gender, race, history of hypertension, diabetes, and cardiovascular disease. The results include hazard ratios and 95% confidence intervals between the two medications within each subgroup. The footnote indicates that "Other" includes multiple ethnicities. Baseline Framingham risk score and electrocardiographic measures appear to have been adjusted.*
Figure 4 - losartan fig4
This appears to be a graphical representation of the results of a clinical trial comparing the effects of Losartan Potassium Tablets versus Placebo on reducing the risk of an unspecified event in a group of patients. The x-axis may represent the time frame of the trial in months. The y-axis may represent the percentage of patients experiencing the event, with the percentage decreasing in the group taking the Losartan Potassium Tablets compared to the placebo group. A calculated risk reduction of 16.1% with a p-value of 0.022 indicates a statistically significant effect in favor of the Losartan Potassium Tablets.*
Structure - losartan str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.